Chen Haidan, Pang Tikki
College of Humanities and Development Studies, China Agricultural University, Beijing, China .
Lee Kuan Yew School of Public Policy, National University of Singapore, 469 C Bukit Timah Road, Singapore 259772, Singapore .
Bull World Health Organ. 2015 Feb 1;93(2):113-7. doi: 10.2471/BLT.14.138420. Epub 2014 Nov 24.
The progress in genomic research has led to increased sampling and storage of biological samples in biobanks. Most biobanks are located in high-income countries, but the landscape is rapidly changing as low- and middle-income countries develop their own. When establishing a biobank in any setting, researchers have to consider a series of ethical, legal and social issues beyond those in traditional medical research. In addition, many countries may have inadequate legislative structures and governance frameworks to protect research participants and communities from unfair distribution of risks and benefits. International collaborations are frequently being created to support the establishment and proper running of biobanks in low- and middle-income countries. However, these collaborations cause cross-border issues – such as benefit sharing and data access. It is thus necessary to define and implement a fair, equitable and feasible biobank governance framework to ensure a fair balance of risks and benefits among all stakeholders.
基因组研究的进展导致生物样本库中生物样本的采集和存储量增加。大多数生物样本库位于高收入国家,但随着低收入和中等收入国家建立自己的生物样本库,这种情况正在迅速改变。在任何情况下建立生物样本库时,研究人员都必须考虑一系列超出传统医学研究范畴的伦理、法律和社会问题。此外,许多国家可能没有足够的立法结构和治理框架来保护研究参与者和社区免受风险和利益不公平分配的影响。国际合作经常被建立起来,以支持低收入和中等收入国家生物样本库的建立和正常运作。然而,这些合作引发了跨境问题,如利益分享和数据访问。因此,有必要定义并实施一个公平、公正且可行的生物样本库治理框架,以确保所有利益相关者之间风险和利益的公平平衡。